Page last updated: 2024-12-07
3-heptadecylcatechol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-heptadecylcatechol : Catechol substituted at position 3 with a heptadecyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 119222 |
| CHEBI ID | 59112 |
| SCHEMBL ID | 1614566 |
| MeSH ID | M0107510 |
Synonyms (18)
| Synonym |
|---|
| 3-heptadecylbenzene-1,2-diol |
| 3-heptadecylpyrocatechol |
| 3-heptadecylcatechol |
| 3-heptadecyl-1,2-benzenediol |
| 3-n-heptadecylpyrocatechol |
| CHEBI:59112 , |
| 3-n-heptadecylcatechol |
| 5862-27-1 |
| HDC , |
| 1,2-benzenediol, 3-heptadecyl- |
| 29r0483xlz , |
| unii-29r0483xlz |
| EPITOPE ID:122678 |
| (17:0)-urushiol [mi] |
| heptadecylcatechol |
| SCHEMBL1614566 |
| DTXSID60207331 |
| Q27126465 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " High doses produced a greater degree of hyposensitization regardless of the dosage schedule used." | ( Immunologic studies of poisonous Anacardiaceae: oral desensitization to poison ivy and oak urushiols in guinea pigs. ElSohly, MA; Murphy, JC; Watson, ES, 1983) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| catechols | Any compound containing an o-diphenol component. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||